Tentative Scientific Agenda


Day 1 : 23rd July 2022 | Saturday
Malaysian
Time
Session Type Speaker Moderator/ Session Chair Title of Presentation
11:20-11:40 Sponsored Symposium 1 - Roche Dr Mastura Md Yusof   Reimagine Breast Cancer Care with Innovation
Key Clinical Data of the Fixed Dose Combination of Pertuzumab and Trastuzumab for subcutaneous injection (PH FDC SC)
11:40-12:00 Sponsored Symposium 2 – (Illumina, Inc.) Dr Chonglei, Bi   Enabling Next Level Comprehensive Genomic Profiling with Gold-Standard Homologous Recombination Deficiency (HRD) Insights
12:00 - 12:05 Welcome Address
12:05 - 13:10 Session 1 - Breast Local/ Regional/ Adjuvant/ Metastatic
12:05-12:15 Presentation Dr Shazril Imran, Malaysia   LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
12:15-12:25 Presentation Dr Michael Gnant, USA   Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial.
12:25-12:35 Presentation Dr Rangasamy Ramachandran, Malaysia   Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.
12:35-12:45 Presentation Dr Daniel Gan, Malaysia   Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04 , a randomized, phase 3 study
12:45-12:55 Presentation Dr Vaishnavi Jeyasingam, Malaysia   Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
12:55-13:00 Quick Quiz Question
13:00-13:15 Exhibition Tour Break
13:15-13:35 Sponsored Symposium 3 - Zuillig Pharma Dr Jennifer Leong Siew Mooi   Updates on CDK4/6 Inhibitors in the Management of HR+HER2- Metastatic Breast Cancer
13:35-14:05 Session 2 - Head & Neck
13:35-13:45 Presentation Dr Aldrin Jasper Placidus, Malaysia   Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma.
13:45-13:55 Presentation Dr Sangeeta Vahnalingam, Malaysia   Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, andomized phase III trial.
13:55-14:05 Presentation Dr Lee Hong, Malaysia   An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial).
14:05 - 14:25 Session 3 - Upper GI
14:05-14:15 Presentation Dr Kumutha Chalaya, Malaysia Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
14:15-14:25 Presentation Dr Izzati Binti Wan Maharuddin, Malaysia   A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
14:25 - 15:10 Session 4 - Lower GI
14:25-14:35 Presentation Dr Jeanne Tie, Australia   Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.
14:35-14:45 Presentation Dr Sandya Subramaniam, Malaysia   Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial
14:45-14:55 Presentation Dr Antonio Avallone, Italy   Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer
14:55-15:05 Presentation Prof. Andrea Cercek, USA   Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
15:05-15:10 Quick Quiz Question
15:10-15:30 Exhibition Tour Break
15:30-16:15 Sponsored Session 4 - BMS Dr Elizabeth Smyth Prof Ho Gwo Fuang Transforming management of GI cancer with immuno-oncology
16:15-16:45 Session 5 - Gynaecology
16:15-16:25 Presentation Dr Bradley Monk, USA   ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer
16:25-16:35 Presentation Dr Katherine The Hooi Lay, Malaysia   Mirvetuximab sorvatansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha: FRa expression: characterization of antitumor activity in the SORAYA study
16:35-16:45 Presentation Dr Patricia Shamani Soosainathan, Malaysia   Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
16:45-18:00 Session 6 - Genitourinary
16:45-16:55 Presentation Dr Lim Chun Sen, Malaysia   EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study
16:55-17:05 Presentation Prof Adlinda Alip, Malaysia   Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
17:05-17:15 Presentation Dr Junie Khoo, Malaysia   The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.
17:15-17:25 Presentation Dr Faizah Binti Ab Muin, Malaysia Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
17:25-17:35 Presentation Dr Vance Koi, Malaysia   Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management.
17:35-17:45 Presentation Dr Michael Hofman, Australia   TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603).
17:45-17:55 Presentation Prof Marniza Saad, Malaysia   Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
17:55-18:00 Quick Quiz Question
END OF DAY 1
 
Day 2 : 24th July 2022 | Sunday
Malaysian
Time
Session Type Speaker Moderator/ Session Chair Title of Presentation
10:55-11:00 Day 2 Opening Remarks from Committee Member
11:00-11:50 Session 7 - Lung Cancer (NSCLC)
11:00-11:10 Presentation Dr Ibtisam Binti Muhamad Nor   EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.
11:10-11:20 Presentation Dr Yusra Binti Hadi, Malaysia   Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis.
11:20-11:30 Presentation Dr Norhidayu Salimin, Malaysia   Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
11:30-11:40 Presentation Dr Voon Pei Jye, Malaysia   KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
11:40-11:50 Presentation Dr Karen Reckamp, USA   Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A.
11:50-12:25 Sponsored Symposium 5 - BMS Prof Ravindran Kanesvaran  Dr Lim Chun Sen Raising the bar for 2L RCC patients with Immunotherapy
12:25-13:00 Session 8 – Lung Cancer (Small Cell)
12:25-12:35 Presentation Prof. Apar Kishor Ganti, USA   Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).
12:35-12:45 Presentation Prof. Charles Rudin, USA   SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
12:45-12:50 Quick Quiz Question
12:50-13:10 Exhibition Tour Break
13:10-13:30 Sponsored Session 6 - Astellas Prof Ravindran Kanesvaran   Enzalutamide for the treatment of mHSPC : A closer look at the ARCHES and ENZAMET clinical studies
13:30-13:50 Session 9 – Musculoskeletal
13:30-13:40 Presentation Dr Teh Kok Hoi, Malaysia   Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
13:40-13:50 Presentation Dr Eng Jie Yi, Malaysia   Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).
13:50-14:25 Session 10 – Central Nervous Tumour
13:50-14:00 Presentation Dr Chan Min Jun, Malaysia   Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group.
14:00-14:10 Presentation Dr Kisha Subramaniam, Malaysia   Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
14:10-14:20 Presentation Dr Audi Adawiah Sulaiman Shah, Malaysia   Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.
14:20-14:25 Quick Quiz Question
14:25-14:55 Session 11 – Melanoma/ Skin Cancer
14:25-14:35 Presentation Dr Teo Yin Keong, Malaysia   Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study.
14:35-14:45 Presentation Dr Tan Ai Lian, Malaysia   Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
14:45-14:55 Presentation Dr Ooi Kai Yun, Malaysia   Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047
14:55-15:15 Exhibition Tour Break
15:15-15:35 Sponsored Symposium 7 – IPSEN Dr Daniel Heng   Expanding Horizons - Optimizing frontline strategy in advanced RCC 
15:35 -  16:10 Session 12 - Cancer Care & Regulatory policy/ Health Service Research & Quality Improvement
15:35-15:45 Presentation Dr Noor Nabila Mohamad, Malaysia Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.
15:45-15:55 Presentation Dr Izzati Rosli, Malaysia Evaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice.
15:55-16:05 Presentation Dr.Vickee Rajeswaran, Malaysia The PACES Study: A controlled before and after pragmatic trial of a cancer clinic based intervention to increase early referral to specialist palliative care.
16:05-16:10 Quick Quiz Question
16:00 onwards Award Declaration & Valedictory 






Sponsors


Diamond Sponsors


Knowledge Partner


Gold Sponsor


Regular Sponsor


Presented By